id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0080-0004,FDA,FDA-2012-D-0080,Guidance on Oversight of Positron Emission Tomography Drug Products - Questions and Answers,Notice,Notice of Availability,2012-12-04T05:00:00Z,2012,12,2012-12-04T05:00:00Z,,2012-12-04T16:38:40Z,2012-29157,0,0,090000648117e3df
FDA-2012-D-0080-0005,FDA,FDA-2012-D-0080,Guidance on Oversight of Positron Emission Tomography Drug Products - Questions and Answers,Other,Guidance,2012-12-04T05:00:00Z,2012,12,2012-12-04T05:00:00Z,,2024-11-12T05:08:30Z,,1,0,090000648117e684
FDA-2012-D-0080-0002,FDA,FDA-2012-D-0080,Draft Guidance; Oversight of Positron Emission Tomography Drug Products,Other,Guidance,2012-02-27T05:00:00Z,2012,2,2012-02-27T05:00:00Z,2012-05-30T03:59:59Z,2019-10-21T14:02:22Z,,0,0,0900006480fc3894
FDA-2012-D-0080-0001,FDA,FDA-2012-D-0080,Draft Guidance; Availability: Oversight of Positron Emission Tomography Drug Products,Notice,Notice of Availability,2012-02-27T05:00:00Z,2012,2,2012-02-27T05:00:00Z,2012-05-30T03:59:59Z,2012-02-27T14:08:09Z,2012-04427,0,0,0900006480fc30a5